Bayer HealthCare AG discovers, develops, manufactures, and markets products that help to prevent, diagnose, and treat diseases for humans and animals worldwide. The company operates through four divisions: Animal Health, Consumer Care, Medical Care, and Pharmaceuticals. The Animal Health division produces and distributes various animal health and care products, which include flea and tick-control solutions, anti-infective products, and endoparasitics for farm and companion animals. The Consumer Care division offers over-the-counter products, such as analgesics, gastrointestinal products, dermatological/topical products, cough and cold remedies, and multivitamins and dietary supplements. It s...
Building Q 30
Founded in 1863
Janssen Pharmaceuticals, Inc. and Bayer Healthcare Announces Results from the Venture-AF Trial
May 14 15
Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare announced results from the VENTURE-AF trial. The study explored the potential of once-daily XARELTO® (rivaroxaban) as an alternative to vitamin K antagonists (VKA), used to reduce the risk of blood clots, in people with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation, a frequently used interventional procedure to remove abnormal tissue in the heart that is causing the irregular heartbeat. The results were presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions, and published in the European Heart Journal. Over the past decade, the number of catheter ablation procedures has risen dramatically in the United States, with more than 93,000 procedures performed from 2000-2010. Current guidelines recommend uninterrupted anticoagulation before, during and after the procedure to help prevent life-threatening blood clots. The VENTURE-AF study is the first global, prospective, randomized trial of any novel oral anticoagulant (NOAC) in this high-risk patient population. VENTURE-AF was a 248-patient, Phase 3b trial. For patients treated during or after the catheter ablation procedure, there was one major bleed in the VKA group, as defined by the ISTH scale, compared to zero for rivaroxaban. There were no major bleeds in either group using GUSTO- and TIMI-defined scales. The majority of bleeding that occurred in the study was mild or insignificant. There was one ischemic stroke and one vascular death in the VKA arm compared to none for rivaroxaban. Serious adverse events were comparable between both treatment strategies with 17 in the rivaroxaban group and 20 in the VKA group. VENTURE-AF was intentionally designed as an exploratory study and thus no formal statistical superiority or non-inferiority analysis was planned. VENTURE-AF is a part of the EXPLORER global cardiovascular research program for XARELTO®. The EXPLORER program includes 11 trials assessing the safety and efficacy of XARELTO® in high-risk patient populations, including those with chronic heart failure, coronary artery disease, peripheral artery disease, acute coronary syndrome and embolic stroke of undetermined source. By the time of its completion, more than 275,000 patients will have participated in the XARELTO® clinical development program, other completed and ongoing clinical trials, investigative registries, and non-interventional studies.
HealthCare Reports Earnings Results for the First Quarter of 2015
Apr 30 15
HealthCare reported earnings results for the first quarter of 2015. For the quarter, sales increased by 7% to EUR 5.7 billion. Adjusted EBITDA increased by 24% to EUR 1.6 billion. The strong business performance, the contributions from the acquired businesses and positive currency effects of approximately EUR 50 million drove the improvement in earnings. Earnings growth was held back by increased investments in R&D as well as increased expenses from marketing and sale.
Bayer HealthCare Reports China Sales Results for the Year 2014
Apr 30 15
Bayer HealthCare reported china sales results for the year 2014. For the year, the company reported EUR 1.659 billion or CNY 13.55 billion sales value in China in 2014, rising 14% from a year earlier. Sales value for healthcare prescription drugs hiked 15% and that for health consumer and animal health products increased 26% and 11%.